Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.

Neurology - 11 Mar 2014

Rosas Herminia D, Doros Gheorghe, Gevorkian Sona, Malarick Keith, Reuter Martin, Coutu Jean-Philippe, Triggs Tyler D, Wilkens Paul J, Matson Wayne, Salat David H, Hersch Steven M

Abstract excerpt

OBJECTIVE: To assess the safety and tolerability of high-dose creatine, the feasibility of enrolling premanifest and 50% at-risk subjects in a prevention trial, and the potential of cognitive, imaging, and blood markers. METHODS: Sixty-four eligible consenting participants were randomly allocated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Creatine
Share to Atrophy
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diffusion Magnetic Resonance Imaging

Share to Double-Blind Method

Share to Feasibility Studies

Share to Huntington Disease

Share to Prodromal Symptoms

Source

Open in PubMed Open full text

Identifiers

PMID: 24510496
DOI: 10.1212/WNL.0000000000000187
PMCID: PMC3959748

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-24510496-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.PMID 24510496Read ↗

MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD studySemantic proximity Read ↗

Bioenergetic dysregulation in the basal ganglia and cerebellum of patients with premanifest and manifest Huntington’s diseaseSemantic proximity Read ↗

Prospects for neuroprotective therapies in prodromal Huntington's diseaseSemantic proximity Read ↗

Protocol for a randomised controlled feasibility trial of HD-DRUM, a rhythmic movement training application for cognitive and motor symptoms in people with Huntington’s diseaseSemantic proximity Read ↗

Longitudinal Evaluation of Magnetic Resonance Spectroscopy Metabolites as Biomarkers in Huntington’s DiseaseSemantic proximity Read ↗

A historical approach to creatine supplementation research over the last decades: From athletes to everyoneSemantic proximity Read ↗

Neurochemical correlates of caudate atrophy in Huntington's disease.Semantic proximity Read ↗

Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease.Semantic proximity Read ↗

Creatine-supplemented diet extends Purkinje cell survival in spinocerebellar ataxia type 1 transgenic mice but does not prevent the ataxic phenotype.Semantic proximity Read ↗

Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.Semantic proximity Read ↗

Evaluation of psychological symptoms among presymptomatic HD gene carriers as measured by selected MMPI scales.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.